N -Acetylcysteine and a Specialized Preventive Intervention for Individuals at High Risk for Psychosis: A Randomized Double-Blind Multicenter Trial.

Sven WasserthalAna MuthesiusRené HurlemannStephan RuhrmannStefanie J SchmidtMartin HellmichFrauke Schultze-LutterJoachim KlosterkötterHendrik MüllerAndreas Meyer-LindenbergTimm B PoepplHenrik WalterDusan HirjakNikolaos KoutsoulerisAndreas J FallgatterAndreas BechdolfAnke Brockhaus-DumkeChristoph MulertAlexandra PhilipsenJoseph Kambeitz

Published in: Schizophrenia bulletin open (2024)

The superiority of NAC or IPPI in preventing psychosis in patients with CHR-P compared to controls could not be statistically validated in this trial. However, results indicate a consistent pattern that warrants further testing of NAC as a promising and well-tolerated intervention for CHR patients in future trials with adequate statistical power.

Keyphrases

phase iii
study protocol
randomized controlled trial
double blind
clinical trial
phase ii
end stage renal disease
transcription factor
ejection fraction
newly diagnosed
chronic kidney disease
placebo controlled
prognostic factors
open label
peritoneal dialysis
patient reported outcomes
genome wide analysis